Related Experiment Videos

[Immunosuppressive effect of cyclophosphamide in experimental coagulase-negative staphylococcal infection]

G Nagy1, F E Pappné, P Kovács

  • 1Debreceni Orvostudományi Egyetem, Mikrobiológiai Intézet.

Orvosi Hetilap
|May 16, 1993
PubMed

Insights

Cyclophosphamide (CTX) treatment significantly increases mouse susceptibility to coagulase-negative staphylococci infections. This immunosuppression leads to higher mortality, increased bacterial persistence, and more severe disease outcomes.

Area of Science:

  • Immunology
  • Microbiology
  • Pharmacology

Background:

  • Cyclophosphamide (CTX) is an immunosuppressive chemotherapeutic agent.
  • Coagulase-negative staphylococci (CoNS) are opportunistic pathogens.
  • The impact of CTX-induced immunosuppression on CoNS infection severity is not fully elucidated.

Purpose of the Study:

  • To investigate the effect of cyclophosphamide pretreatment on the susceptibility and disease course of mice infected with coagulase-negative staphylococci.

Main Methods:

  • BALB/c mice were administered cyclophosphamide (200 mg/kg, i.p.).
  • Mice were subsequently infected with Staphylococcus epidermidis, S. haemolyticus, or S. saprophyticus at varying inocula.
  • Lethality, organ bacterial load, peritoneal abscesses, adhesions, and splenomegaly were assessed.

Main Results:

  • Cyclophosphamide-treated mice exhibited significantly higher mortality rates and bacterial organ persistence compared to controls.
  • Increased incidence of peritoneal abscesses and adhesions was observed in CTX-pretreated mice.
  • Pronounced splenomegaly suggested a compensatory immune response post-immunosuppression.

Conclusions:

  • Cyclophosphamide treatment enhances susceptibility to coagulase-negative staphylococci infection in mice.
  • CTX administration leads to a more severe clinical course of staphylococcal infections.
  • These findings highlight the critical role of immune status in managing opportunistic bacterial infections.

Related Concept Videos